Small Molecule PD-1 Inhibitors for T Cell Exhaustion

The patent converts the harmful PD-1/PD-L1 inhibitory interaction into a beneficial effect by using small molecule compounds to block this interaction. The compounds specifically inhibit PD-1 binding to PD-L1 and CD80, thereby converting the exhaustion-inducing mechanism into an immune-restoring mechanism. This is achieved through structural compounds that compete with PD-L1 for binding to PD-1, preventing the inhibitory signal while maintaining the ability to reverse exhaustion in chronically stimulated T cells.

The patent employs small molecule compounds as disposable, orally administrable alternatives to expensive monoclonal antibodies. These small molecules can be synthesized at lower cost, administered orally rather than requiring intravenous infusion, and do not require complex manufacturing processes. The compounds achieve comparable immune restoration effects while eliminating the need for complex antibody production, purification, and administration infrastructure.

The patent achieves selective inhibition of PD-1/PD-L1 and PD-1/CD80 interactions through small molecules that specifically target the binding interface. The compounds are designed to bind selectively to PD-1 or its ligands with high affinity and specificity, minimizing off-target effects. This localized specificity is achieved through rational drug design that focuses on the precise molecular interactions at the PD-1 binding site, ensuring that only the intended immune checkpoint pathway is modulated while other cellular functions remain unaffected.